• Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
Wednesday, November 18, 2026
No Result
View All Result
Subscribe Now
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Exploring Diversity: ‘Ten Lives’ Showcases the Varied Economic Journeys of Americans

    Exploring Diversity: ‘Ten Lives’ Showcases the Varied Economic Journeys of Americans

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
The Insight Post
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Exploring Diversity: ‘Ten Lives’ Showcases the Varied Economic Journeys of Americans

    Exploring Diversity: ‘Ten Lives’ Showcases the Varied Economic Journeys of Americans

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
No Result
View All Result
No Result
View All Result
Home International

Activists Challenge Pharma Company Gilead Over HIV Medication — Global Issues

by Theinsightpost
August 2, 2024
in International
0 0
0
Activists Challenge Pharma Company Gilead Over HIV Medication — Global Issues


Activists protest during the 25th International AIDS Conference (AIDS2024) in Munich over a affordable pricing for a drug currently sold by pharmaceutical firm Gilead. Credit: Ed Holt/IPS
  • by Ed Holt (munich)
  • Friday, August 02, 2024
  • Inter Press Service

MUNICH, Aug 02 (IPS) – Campaigners and experts have demanded a breakthrough HIV intervention hailed as “the closest thing to an HIV vaccine” must be made available as soon and as cheaply as possible to all who need it as its manufacturer faces protests over its pricing.

Activists led a massive protest during the 25th International AIDS Conference (AIDS2024) in Munich last week as a study was presented showing lenacapavir—a drug currently sold by pharmaceutical firm Gilead for more than USD 40,000 per year as an HIV treatment—could be sold for USD 40 per year as a form of pre-exposure prophylaxis (PrEP) to help prevent HIV infection.

Community groups working in prevention, as well as experts and senior figures at international organizations fighting HIV, called on the company to ensure it will be priced so it is affordable for low- and middle-income countries (LMICs), which account for 95 percent of HIV infections.

“It is no exaggeration to call lenacapavir a game changer. It could be life-changing for some populations. We need to see it produced generically and supplied to all low- and middle-income countries to the people who need it,” said Dr. Helen Bygrave, chronic disease advisor at Medecins sans Frontiere’s (MSF) Access Campaign.

During the event, data from a trial of lenacapavir, a twice-yearly injectable, were presented. The results of the trial were announced by pharmaceutical firm Gilead last month and showed the drug offered 100% protection to more than 5,000 women in South Africa and Uganda.

Many experts and community leaders helping deliver HIV interventions who spoke to IPS described the drug as a real “game changer,” offering not just spectacular efficacy but relative ease and discretion in delivery—the latter key in combating stigma connected with HIV prevention intervention in some societies—compared to other interventions, such as oral PrEP.

But they warned there were likely to be challenges to access, with cost expected to be the main barrier.

Lenacapavir is currently approved only as a form of HIV treatment at a price of USD 42,000 per person per year.

While as a PrEP intervention it would be expected to be sold at a much lower price, an abstract presented at the conference showed that it could cost just USD 40 a year for every patient.

In a statement put out following the protests, Gilead said it was developing “a strategy to enable broad, sustainable access globally” but that it was too early to give details on pricing.

Critics claimed Gilead was not being transparent in its statement—the company talked of being committed to access pricing for high-incidence, resource-limited countries rather than specifically low- and middle-income countries—and there are fears that the price at which it is eventually made available as PrEP will be so high as to put it out of reach of the countries that are struggling most with the HIV epidemic.

“Cabotegravir, a two-month injectable form of PrEP, is currently being procured by MSF for low-income countries for USD 210 per person per year. We would not expect to be higher than that, and we would hope it would be more ‘in the ballpark’ of  USD 100 per person per year,” said Bygrave.

She added that “questions have been asked of Gilead about its pricing for lenacapavir, and the company has been pretty vague in its answers.”

“Civil society needs to put continued pressure on Gilead about this issue because, without that pressure, I do not trust Gilead to do the right thing,” Bygrave, who took part in protests at the conference against Gilead’s pricing, said.

Some speakers at the conference set out a series of demands for the firm.

Winnie Byanyima, Executive Director of UNAIDS, called on Gilead to license generic manufacturers to produce it more affordably through mechanisms such as the Medicines Patent Pool (MPP), a UN-backed programme negotiating generics agreements between originators and generic pharmaceutical companies.

Others, such as keynote speaker Helen Clark, Chair of the Global Commission on Drug Policy, said such interventions must be seen as “common global goods, and ways must be found to make them accessible to all.”

“The pharmaceutical industry has been the beneficiary of much public research investment. With respect to HIV/AIDS, it has benefited from the mobilization of scientists and engaged communities who have advocated for investment in R&D and treatments. Prima facie, the notion that the companies can then make great profits from and not share the intellectual property created is wrong,” she said.

Others went even further, accusing some pharmaceutical firms of being parties to the creation of a de facto global two-tier system for medicine supply.

“Companies must share their medicines. We cannot accept an apartheid in access to medicine in which the lives of those living in the Global South are not regarded as having the same value as the lives in the North,” Archbishop Dr Thabo Makgoba, Archbishop of the Anglican Church of Cape Town and HIV advocate, said at a UNAIDS press event during the conference.

Some of those who work with key populations stressed the need to push through all necessary approvals and set lenacapavir’s price at an accessible level as quickly as possible to save lives.

“It’s great to have innovation and get important new tools in the fight against HIV. But the question is: how long will it take to get them to the people who need them? Until then, they are just a great announcement—like a beautiful picture hanging up there that you can see but cannot actually touch. We need to give communities the funding and the tools they need to do their vital work,” Anton Basenko, Chair of the Board of the International Network of People who Use Drugs (INPUD), told IPS.

The calls came as campaigners stressed the exceptional potential of lenacapavir. It is not only its astonishing efficacy, but also its relative ease and discretion of delivery, which experts are excited about.

Stigma around HIV prevention, such as oral PrEP, which involves taking daily tablets, has been identified as a major barrier to the uptake of HIV interventions in some regions.

Some HIV healthcare specialists at the conference told IPS they had seen cases of women leaving clinics with bottles of tablets and, as soon as they heard them rattling in the bottle, threw them into the bin outside the clinic because the noise would tell others they were taking the tablets and leave them open to potential discrimination, or even gender-based violence.

“The lack of oral PrEP uptake and adherence among women and girls is due to a number of factors, such as stigma and worries about being seen with a huge bottle of pills. What about if you are in a relationship and your partner sees the bottle and starts asking whether you are cheating on them or something?

“A woman could go and get a lenacapavir injection a couple of times a year and no one would have to even know and she wouldn’t have to think about taking pills every day and just get on with her life. This drug could change lives completely. I would definitely take it if it was available,” Sinetlantla Gogela, an HIV prevention advocate from Cape Town, South Africa, told IPS.

The concerns around access to lenacapavir at an affordable price for low and middle income countries come against a background of record debt levels among poor countries, which experts say could have a severe negative impact on the HIV epidemic.

A recent report from the campaign group Debt Relief International showed that more than 100 countries are struggling to service their debts, resulting in them cutting back on investment in health, education, social protection and climate change measures.

Speakers at the conference repeatedly warned these debts had to be addressed to ensure HIV programmes, whether they include lenacapavir or not, continue. Many called for immediate debt relief in countries.

“African debt needs to be restructured to let countries get hold of the medicines they need,” said Byanyima.

“Drop the debt; it is choking global south countries, denying us what we need for health. Please let us breathe,” said Makgoba.

IPS UN Bureau Report

Follow @IPSNewsUNBureau
Follow IPS News UN Bureau on Instagram

© Inter Press Service (2024) — All Rights ReservedOriginal source: Inter Press Service

Where next?

Related news

Browse related news topics:

Latest news

Read the latest news stories:

  • Activists Challenge Pharma Company Gilead Over HIV Medication Friday, August 02, 2024
  • 79 Years After Hiroshima & Nagasaki: A Grim Reminder of Nuclear Annihilation Thursday, August 01, 2024
  • Cambodia’s Young Environmental Activists Pay a Heavy Price Thursday, August 01, 2024
  • Economic Prospects in Asia & the Pacific – Celebrate Resilience, Prepare for Headwinds Thursday, August 01, 2024
  • US-Russia prisoner swap ‘an unprecedented diplomatic act’, rights experts says Thursday, August 01, 2024
  • in call to Iranian Foreign Minister, Guterres underlines need for de-escalation in the Middle East Thursday, August 01, 2024
  • Famine now prevalent in parts of war-torn Sudan Thursday, August 01, 2024
  • Gaza: UNRWA programme aims to get children ‘back to learning’ Thursday, August 01, 2024
  • Guinea: Senior UN officials welcome verdict in 2009 stadium massacre trial Thursday, August 01, 2024
  • Femicide and Reproductive Violence Harm African Women, Girls Wednesday, July 31, 2024

In-depth

Learn more about the related issues:

Share this

Bookmark or share this with others using some popular social bookmarking web sites:

Link to this page from your site/blog

<p><a href="https://www.globalissues.org/news/2024/08/02/37360">Activists Challenge Pharma Company Gilead Over HIV Medication</a>, <cite>Inter Press Service</cite>, Friday, August 02, 2024 (posted by Global Issues)</p>

… to produce this:

Activists Challenge Pharma Company Gilead Over HIV Medication, Inter Press Service, Friday, August 02, 2024 (posted by Global Issues)





Source link

ShareTweetSend
Previous Post

Archaeologists Find a 2,400-Year-Old ‘Pot of Gold’ in Turkey

Next Post

USA Basketball doctor shares what it’s like to treat athletes at the Olympics

Related News

Unauthorized Entry Blocked
International

Unauthorized Entry Blocked

November 18, 2026
L3Harris Telecom System Upgrade Triggers Ground Stop, Says Duffy
International

L3Harris Telecom System Upgrade Triggers Ground Stop, Says Duffy

November 15, 2026
Pentagon: U.S. Military Faces Challenges Due to Ongoing Ukraine Support
International

Pentagon: U.S. Military Faces Challenges Due to Ongoing Ukraine Support

November 14, 2026
Appeals Court Revives Injury Claim Against Motel 6 After Missouri Guest’s Ice Slip-Up Incident
International

Appeals Court Revives Injury Claim Against Motel 6 After Missouri Guest’s Ice Slip-Up Incident

November 13, 2026
Next Post
USA Basketball doctor shares what it’s like to treat athletes at the Olympics

USA Basketball doctor shares what it's like to treat athletes at the Olympics

Discussion about this post

Subscribe To Our Newsletters

    Customer Support


    1251 Wilcrest Drive
    Houston, Texas
    77042 USA
    Call-832.795.1420
    e-mail – news@theinsightpost.com

    Subscribe To Our Newsletters

      Categories

      • Africa
      • Africa-East
      • African Sports
      • American Sports
      • Arts
      • Asia
      • Australia
      • Business
      • Business Asia
      • Business- Africa
      • Canada
      • Defense
      • Education
      • Egypt
      • Energy
      • Entertainment
      • Europe
      • European Soccer
      • Finance
      • Germany
      • Ghana
      • Health
      • Insight
      • International
      • Investing
      • Japan
      • Latest Headlines
      • Life & Living
      • Markets
      • Mobile
      • Movies
      • New Zealand
      • Nigeria
      • Politics
      • Scholarships
      • Science
      • South Africa
      • South America
      • Sports
      • Tech
      • Travel
      • Travel-Africa
      • UK
      • USA
      • Weather
      • World
      No Result
      View All Result

      Recent News

      Vintage Photo of Robert Pattinson and Daniel Craig Gains New Significance Amid Bond Casting Developments

      Vintage Photo of Robert Pattinson and Daniel Craig Gains New Significance Amid Bond Casting Developments

      November 18, 2026
      Top 7 Retirement Threats and Effective Strategies to Navigate Them

      Top 7 Retirement Threats and Effective Strategies to Navigate Them

      November 18, 2026
      Charting the Future: Unveiling the TEFCA 2026-2027 Workplan and Innovative Monthly Metrics

      Charting the Future: Unveiling the TEFCA 2026-2027 Workplan and Innovative Monthly Metrics

      November 18, 2026
      Inevitable Buyer’s Remorse Looms Over Midterm Elections

      Inevitable Buyer’s Remorse Looms Over Midterm Elections

      November 18, 2026
      • Home
      • Advertise With Us
      • About Us
      • Corporate
      • Consumer Rewards
      • Forum
      • Privacy Policy
      • Social Trends

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      Welcome Back!

      Login to your account below

      Forgotten Password?

      Retrieve your password

      Please enter your username or email address to reset your password.

      Log In

      Add New Playlist

      We are using cookies to give you the best experience on our website.

      You can find out more about which cookies we are using or switch them off in .

      No Result
      View All Result
      • Home
      • Insight
      • Blog
      • Business
      • Entertainment
      • Health
      • Politics
      • Shop
        • Gift Shop
        • Value Shop
        • Store
        • Bargain Shop
        • Discount
      • Sports
      • Tech
      • Travel
      • USA
      • Video
      • World
        • Asia
        • Africa
        • South America
        • North America
        • Europe
        • Oceania

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      The Insight Post
      Powered by  GDPR Cookie Compliance
      Privacy Overview

      This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

      Strictly Necessary Cookies

      Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

      Cookie Policy

      More information about our Cookie Policy